Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01309230 · ClinicalTrials.gov registry record · Phase 2
A Trial of FANG™ Vaccine for Participants With Ovarian Cancer
A Phase 2 study, sponsored by Gradalis.
- Completed
- Registry status
- Phase 2
- Development phase
- 39
- Enrollment target
NCT01309230 is a Phase 2 study that has completed, run by Gradalis. The registered enrollment target is 39 participants.
The verdict
NCT01309230, a Phase 2 study, has completed, sponsored by Gradalis.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 39 participants
- Enrollment target
Study Summary
This was a clinical trial for women with ovarian cancer scheduled to have an operation to remove the cancerous tissue. The cancer cells removed during the planned surgery were used to attempt to make the investigational product, named Vigil. Vigil is considered an immunotherapy. In this study, participants who met the requirements to be in the study and if Vigil was successfully made from the participants cancer cells, participants underwent treatment with their standard chemotherapy regimen. At the end of the standard chemotherapy regimen and if there was no evidence of remaining cancer, participants were randomly assigned to receive the Vigil or would be assigned to the standard of care group, which in this study meant no further treatment was given to the participant. The purpose of this study was to compare the difference between the participants who received Vigil versus the usual care after completion of standard chemotherapy and to determine if Vigil delayed or prevented ovarian cancer from coming back.
Interventions
- BIOLOGICAL Vigil™
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 39 participants |
| Start Date | 2011-03-08 |
| Est. Completion | 2022-02-02 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01309230
The ClinicalTrials.gov registry entry for NCT01309230 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 39 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Gradalis, which has 13 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Vigil™ is the first listed.
NCT01309230 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01309230 about?
NCT01309230 is a clinical study titled "A Trial of FANG™ Vaccine for Participants With Ovarian Cancer". This was a clinical trial for women with ovarian cancer scheduled to have an operation to remove the cancerous tissue. The cancer cells removed during the planned surgery were used to attempt to make the investigational product, named Vigil. Vigil is considered an immunotherapy. In this study, parti...
What is the current status of trial NCT01309230?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 39 participants. The study started on 2011-03-08. Estimated completion is 2022-02-02.
What interventions are being tested in trial NCT01309230?
The interventions under investigation include: Vigil™ (BIOLOGICAL).
Who is sponsoring clinical trial NCT01309230?
This trial is sponsored by Gradalis, which has 13 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.